In short
Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO16 among others, is being tested in adults aged 60 and older who have a history of urinary tract infections. The trials aim to assess the vaccine's ability to prevent serious E. coli infections, its safety profile, and its impact on patients' quality of life.
At a glance
- Vaccine Name
- ExPEC9V (JNJ-78901563)
- Target Population
- Adults aged 60 years and older with a history of urinary tract infections
- Primary Objectives
- Prevent invasive E. coli disease, evaluate safety and immunogenicity
- Administration
- Intramuscular injection
- Key Components
- ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75
- Study Design
- Randomized, double-blind, placebo-controlled Phase 3 trials
- Follow-up Duration
- Up to 3 years post-vaccination
- Key Outcomes
- Prevention of invasive E. coli disease, urinary tract infections, and related hospitalizations
What is ExPEC9V?
ExPEC9V (also known as JNJ-78901563) is an investigational vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. This vaccine is designed to target specific strains of E. coli bacteria that can cause serious infections outside the intestinal tract.
The vaccine contains nine different components (O-serotypes) of E. coli bacteria: ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, and ECOO75. These components are carefully selected to provide protection against the most common and problematic strains of ExPEC.
Who is ExPEC9V intended for?
ExPEC9V is primarily being studied for use in adults aged 60 years and older who have a history of urinary tract infections (UTIs). This group is particularly vulnerable to invasive E. coli infections due to factors such as:
- Weakened immune systems
- Increased susceptibility to UTIs
- Higher risk of complications from bacterial infections
The vaccine may be especially beneficial for older adults who have additional risk factors for invasive ExPEC disease, such as:
- A history of E. coli bloodstream infections (bacteremia) or urosepsis
- Recent hospitalization
- Presence of conditions that increase the risk of complicated UTIs
How does ExPEC9V work?
ExPEC9V is designed to stimulate the immune system to produce antibodies against the nine specific O-serotypes of E. coli included in the vaccine. These antibodies help the body recognize and fight off these harmful bacteria more effectively if exposed to them in the future.
The vaccine is administered as an intramuscular injection, typically in the upper arm (deltoid muscle). It is given as a single dose, which may make it more convenient for older adults compared to vaccines that require multiple doses.
Current Clinical Trials
ExPEC9V is currently being evaluated in Phase 3 clinical trials, which are large-scale studies designed to assess the vaccine's effectiveness and safety in a broader population. Two notable trials are:
- A study comparing ExPEC9V with a high-dose quadrivalent influenza vaccine in adults aged 65 years or older. This trial aims to:
- Evaluate the immune response to both vaccines when given together or separately
- Assess the safety and reactogenicity (expected short-term side effects) of the vaccines
- A large-scale study in adults aged 60 years and older with a history of UTIs. This trial is designed to:
- Determine if ExPEC9V can prevent invasive E. coli infections
- Evaluate the vaccine's ability to reduce UTIs and other E. coli-related illnesses
- Assess the long-term safety and effectiveness of the vaccine
Potential Benefits of ExPEC9V
If proven effective, ExPEC9V could offer several benefits to older adults:
- Reduced risk of serious E. coli infections, including those affecting the blood, kidneys, and other organs
- Fewer hospitalizations due to E. coli-related illnesses
- Decreased incidence of UTIs and associated complications
- Improved quality of life for those prone to recurrent UTIs or at risk for invasive E. coli infections
- Potential reduction in antibiotic use, which could help combat antibiotic resistance
Safety and Side Effects
As with any vaccine, safety is a top priority in the development of ExPEC9V. The ongoing clinical trials are carefully monitoring for any adverse effects. Some potential side effects that may occur include:
- Pain, redness, or swelling at the injection site
- Mild fever or fatigue
- Headache or muscle aches
These side effects are typically mild and short-lived. The clinical trials will provide more comprehensive information about the vaccine's safety profile and any rare or unexpected side effects.
Conclusion
ExPEC9V represents a promising advancement in the prevention of invasive E. coli infections in older adults. As the clinical trials progress, more information will become available about its effectiveness and safety. If successful, this vaccine could significantly improve the health and well-being of many older adults who are at risk for these serious infections.
It's important to note that while the vaccine shows promise, it is still under investigation and not yet approved for general use. Patients should continue to follow their healthcare provider's advice regarding prevention and treatment of UTIs and other E. coli-related infections.